Author

Britney N. Lizama

Cognition Therapeutics (United States)ORCID 0000-0001-5970-3913Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Assay:proteomics· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Anthony O. CaggianoiD· 3 shared Aidan Reaver· 2 shared Duc M. DuongiD· 2 shared Gary C. Look· 2 shared Mary E. HambyiD· 2 shared Nicholas T. SeyfriediD· 2 shared Allan I. LeveyiD· 1 shared C. Williams· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersNeuroscience

Anthony O. CaggianoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cell BiologyExperimental Eye ResearchPeer-reviewedFeb 25, 2026

Sigma-2 Receptor Modulators Alter Low-density Lipoprotein Receptor-mediated Lipid Uptake in Retinal Pigment Epithelial Cells

Britney N. Lizama, Aidan Reaver, Gary C. Look…·Mary E. Hamby

This study shows that sigma-2 receptor modulators increase LDL uptake in RPE cells via TMEM97 and LDLR, supporting their potential therapeutic use in dry AMD.

2 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky

NeurosciencebioRxivPreprintJun 20, 2025

Multi-omics comparative analyses of synucleinopathy models reveal distinct targets and relevance for drug development

Britney N. Lizama, Rick S. Shin, Hilary A. North…·Mary E. Hamby

The paper compares two rat synucleinopathy models using multi-omics data to identify disease mechanisms and drug targets relevant to Parkinson's disease.

DOI 10.1101/2025.06.20.660336

ratproteomics

𝕏 PostBluesky

NeuroscienceNeurobiology of DiseasePeer-reviewedJun 22, 2024

An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimers disease

Britney N. Lizama, H.A. North, K. Pandey…·Madison Hamby

This paper reports exploratory CSF proteomics data from a Phase 2 trial of CT1812 in Alzheimer's disease, identifying pharmacodynamic biomarkers and mechanistic insights.

19 citationstop 3%

humanproteomics

𝕏 PostBluesky